Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | LTK | P29376 | 1/20 | 0.59 |
| ▸ | GRK5 | P34947 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208012 | 1.00 | PARP1 (0.70) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL15840543 | 0.82 | PARP1 (1.00) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL28763423 | 0.82 | PARP1 (0.66) | PARP1TNKSTNKS2GUSBPARP2 | |
| SCHEMBL577862 | 0.82 | PARP1 (0.51) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL17829612 | 0.82 | PARP1 (0.70) | PARP1TNKSTNKS2PARP14PARP2 | |
| SCHEMBL15228758 | 0.82 | PARP1 (0.49) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL20955120 | 0.81 | PARP1 (0.47) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL6928926 | 0.80 | PARP1 (0.62) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL21524673 | 0.78 | PARP1 (0.65) | PARP1AURKADAPK3JAK2PRKD3 | |
| SCHEMBL3423314 | 0.78 | TNKS (0.67) | PARP1TNKSTNKS2GUSBPARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608317-A4 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1608317-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | claimed |
| EP-4674841-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| EP-4444305-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-10-16 | — | — | EP | disclosed |
| EP-4311829-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Nodus Oncology Limited (GB) | 2024-01-31 | — | — | EP | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156386-A2 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2023-08-24 | — | — | WO | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | PARP1 3791/4885AURKA 3290/4885DAPK3 1858/4885 |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | PARP1 2477/4885AURKA 3063/4885DAPK3 3001/4885 |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP3, DPP4 | PARP1 2025/4885AURKA 3211/4885DAPK3 2052/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | PARP1 1840/4885AURKA 4078/4885DAPK3 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.